144 related articles for article (PubMed ID: 36290812)
1. Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy.
Sanford D; Desjardins P; Leber B; Paulson K; Assouline S; Lembo PMC; Fournier PA; Leitch HA
Curr Oncol; 2022 Sep; 29(10):6794-6806. PubMed ID: 36290812
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
Ito T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Conca AG; Del Castillo TB; Girshova L; Martelli MP; Guvenc B; Bui CN; Delgado A; Duan Y; Guijarro BG; Llamas C; Lee JH
Eur J Haematol; 2022 Jul; 109(1):58-68. PubMed ID: 35298049
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
Yoshida C; Kondo T; Ito T; Kizaki M; Yamamoto K; Miyamoto T; Morita Y; Eto T; Katsuoka Y; Takezako N; Uoshima N; Imada K; Ando J; Komeno T; Mori A; Ishikawa Y; Satake A; Watanabe J; Kawakami Y; Morita T; Taneike I; Nakayama M; Duan Y; Garbayo Guijarro B; Delgado A; Llamas C; Kiyoi H
Int J Hematol; 2022 Jul; 116(1):89-101. PubMed ID: 35394258
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review.
Bang SM; Kang KW; Song IC; Llamas C; Duan Y; Jeong JY; Lee JH
J Korean Med Sci; 2023 Nov; 38(44):e345. PubMed ID: 37967874
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India.
Kanakasetty GB; R C; K C L; Dasappa L; Jacob LA; M C SB; K N L; Haleshappa RA; L K R; Saldanha SC; Deepak K; Rajesh P; Asati V
Ann Hematol; 2019 Apr; 98(4):881-888. PubMed ID: 30697642
[TBL] [Abstract][Full Text] [Related]
7. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Ma E; Bonthapally V; Chawla A; Lefebvre P; Swords R; Lafeuille MH; Fortier J; Emond B; Duh MS; Dezube BJ
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):625-636.e3. PubMed ID: 27686689
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
9. Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.
Wang CY; Huang HH; Chen HM; Hsiao FY; Ko BS
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e649-e657. PubMed ID: 33931380
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.
van der Helm LH; Scheepers ER; Veeger NJ; Daenen SM; Mulder AB; van den Berg E; Vellenga E; Huls G
J Hematol Oncol; 2013 Apr; 6():29. PubMed ID: 23587459
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.
Talati C; Dhulipala VC; Extermann MT; Ali NA; Kim J; Komrokji R; Sweet K; Kuykendall A; Sehovic M; Reljic T; Djulbegovic B; Lancet JE
Haematologica; 2020; 105(2):398-406. PubMed ID: 31073071
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.
Russell-Smith TA; Gurskyte L; Muresan B; Mamolo CM; Gezin A; Cappelleri JC; Heeg B
Future Oncol; 2022 May; 18(16):2029-2039. PubMed ID: 35196866
[TBL] [Abstract][Full Text] [Related]
16. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota VK
Leuk Res; 2019 Mar; 78():45-51. PubMed ID: 30716655
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada.
Hu Y; Charaan M; van Oostrum I; Heeg B; Bell T
J Med Econ; 2021; 24(1):150-161. PubMed ID: 33461352
[TBL] [Abstract][Full Text] [Related]
19. Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL).
Borlenghi E; Pagani C; Zappasodi P; Bernardi M; Basilico C; Cairoli R; Fracchiolla N; Todisco E; Turrini M; Cattaneo C; Da Vià M; Ciceri F; Passamonti F; Mancini V; Sciumè M; Cerqui E; Sciumè M; Rossi G
J Geriatr Oncol; 2021 May; 12(4):550-556. PubMed ID: 33097455
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
